Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Teijin: Bonalon, Home Care Business Drive Business
November 24, 2008
- Toho: Net Losses due to Bankruptcy of Fuji Biomedix
November 24, 2008
- Meiji Seika: Sales of Generics Up 38.9%
November 24, 2008
- Nihon Chouzai: Investment in Generics Business Depresses Profitability
November 24, 2008
- Ajinomoto: Pharma Sales Up 1.0% to \42.9 Bil.
November 24, 2008
- QOL: Acquisition Boosts Sales by 52%
November 24, 2008
- BUSINESS NEWS IN BRIEF
November 24, 2008
- Wholesale Business Management Seminar
November 24, 2008
- ASKA, Actavis Create Generic Joint Venture Firm in Japan
November 24, 2008
- Santen to Recover Market Share with Tafluprost
November 24, 2008
- DPC Has Increased Use of Generics in over 60 DPC Hospitals: JHA Survey
November 24, 2008
- Shionogi: Rosuvastatin, Doripenem Drive Business
November 17, 2008
- Home Monitoring Improves QOL of CRD Device Recipents
November 17, 2008
- Ono: Sales Down 7.5%, Long-Listed Products Accounting for over 90% of Total Sales
November 17, 2008
- Makers of Self-Monitoring Devices for Blood Glucose Required to Review Package Inserts
November 17, 2008
- Kowa to Make Livalo a Global Product
November 17, 2008
- Precautions for Cold Remedies Required for Children Less than 2 Years Old
November 17, 2008
- Diovan Ranked No. 1 for 2 Consecutive Months: Rep Track Survey
November 17, 2008
- Korosho Council to Promote Public Education on Cancer
November 17, 2008
- Adapalene to Promote Treatment of Acne in Japan: Prof. Kawashima
November 17, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…